title: Effects of haloperidol and GM1 ganglioside treatment on striatal D2 receptor binding and dopamine turnover.
abstract: Previous studies have shown that whereas exogenous GM1 ganglioside co-administration leads to an increase of haloperidol-induced behavioral supersensitivity, GM1 significantly attenuates the behavioral parameters of dopaminergic supersensitivity when administered after abrupt haloperidol withdrawal. In the present study, the effects of GM1 and haloperidol co-administration (5 mg/kg GM1 i.p. and 1 mg/kg haloperidol i.p., twice daily, for 30 days) as well as the effects of a 3 day treatment with GM1 were investigated in rats withdrawn from haloperidol administration by measuring striatal D2 dopamine receptor binding and dopamine turnover. The results showed that under these two experimental conditions GM1 modified neither the haloperidol-induced striatal D2 dopamine receptor up regulation nor the decrease in dopamine turnover produced by haloperidol withdrawal. These results suggest that the effects of GM1 on behavioral supersensitivity are not related to modifications in dopamine receptor number or affinity and in the synaptic availability of this catecholamine.
authors.affiliation: Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil.
authors.forename: M A
authors.initials: MA
authors.lastname: Vital
authors.forename: J C
authors.initials: JC
authors.lastname: Flório
authors.forename: R
authors.initials: R
authors.lastname: Frussa-Filho
authors.forename: R
authors.initials: R
authors.lastname: De Lucia
authors.forename: S
authors.initials: S
authors.lastname: Tufik
authors.forename: J
authors.initials: J
authors.lastname: Palermo-Neto
mesh_terms: D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism* / Q000648:ultrastructure; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D004334:Drug Administration Schedule; D004357:Drug Synergism; D005677:G(M1) Ganglioside / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D017448:Receptors, Dopamine D2 / Q000187:drug effects* / Q000378:metabolism*; D013134:Spiperone / Q000494:pharmacology; D014316:Tritium
chemical_list: D018492:Dopamine Antagonists; D017448:Receptors, Dopamine D2; D014316:Tritium; D005677:G(M1) Ganglioside; D013134:Spiperone; D006220:Haloperidol; D004298:Dopamine